Genmab A/S in 3 stories
The narratives GMAB.CO currently appears in, with its side and exposure in each.
Bull side
2 stories- China Becomes Pharma's Global R&D Engine
GMAB.CO in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Genmab’s acquisition of ProfoundBio added China-origin antibody-drug conjugate technology and clinical assets to its global oncology portfolio.
- The Patent Cliff Sparks a Biotech Land Grab
GMAB.CO in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Genmab combines validated antibody platforms, royalty income and wholly owned oncology assets, giving it leverage in licensing and acquisition negotiations.
Bear side
1 story- America Imports the World's Drug Prices
GMAB.CO in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Genmab's valuation is supported by royalties and profit shares from drugs such as Darzalex and Epkinly, so lower benchmark prices would reduce downstream economics.